Molecular Imaging in Drug Discovery and Development
Day 1 | Day 2
Download World Pharma Congress Final Brochure or Download Molecular Imaging Brochure
About This Conference:
The Molecular Imaging in Drug Discovery and Development conference is designed to bring together leading molecular imaging experts from industry and academia, as well as scientists who use their services to accelerate pharmaceutical research. The main emphasis will be made on molecular imaging applications/use of imaging biomarkers on various stages of drug discovery and development.
|
WEDNESDAY, JUNE 6
12:30 pm Registration
1:00 Chairperson's Opening Remarks
1:10 Industrialized Imaging in a Pharmaceutical Environment
Dinko Gonzalez Trotter, Ph.D., Director, Image Analysis and Physiology, Merck
1:40 Pre-Clinical/Clinical Development and Use of Novel PET Tracers for Establishing Target Expression or Target Binding
Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.
The chemical properties required for a successful novel PET tracer will be reviewed. Application of novel PET tracers pre-clinically and clinically with a focus on the type of information generated that aids drug decision-making and establishment of proof-of-concept will be discussed. A description of the potential utility of labeled biologics to assess target expression, target binding and patient stratification will be presented.
2:10 Image Analysis Approaches to Quantifying MRI and PET Imaging Data
Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen
Following the acquisition of pre-clinical imaging data, it is often desired to quantify features or derive kinetic parameters, which require not only an understanding of the image acquisition and the (patho)physiology but also a keen knowledge of mathematical and statistical models. The development and integration of these methods are laborious and, to minimize bottlenecks, image and data management systems should be considered. This talk with address issues of image analysis and workflow with a focus on multi-modal, core imaging laboratories.
2:40 Cerenkov Luminescence Imaging (CLI) and its Utility in the Drug Discovery Process
Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company
Cerenkov Luminescence Imaging (CLI) is a recently developed imaging technique which blurs the divide between nuclear and optical imaging. Using common radioisotopes, along with modern CCD imaging equipment, it is possible to image radio-labeled compounds without expensive PET equipment. High throughput increases could reach as high as 10 fold compared to current nuclear imaging techniques by using this technique.
3:10 Drug Evaluation through Imaging Biomarkers: A CRO Perspective
Patrick McConville, Ph.D., CSO & COO, Molecular Imaging, Inc
An overview of the use of multiple pre-clinical imaging modalities for drug evaluation through image-based biomarkers will be provided. Imaging biomarker validation and use will be discussed, and examples using probe facilitated imaging will be highlighted.
3:25 Advanced Techniques in Quantitative Whole Body Autoradiography and Cryo-imaging
Stefan Linehan, Manager, Preclinical Services, XenoBiotic Laboratories, Inc.
Quantitative whole body autoradiography (QWBA) is widely used to provide quantitative tissue distribution data of derived radioactivity from a radiolabeled test article as part of a non-clinical ADME program. Advancements within the field of Cryo-imaging and Quantitative Autoradiography (CIQA) along with 3D modeling techniques provide an innovative approach for observing the site-specific localization of radioactivity and drug-induced or naturally occurring abnormalities. These advancements in CIQA can be used to provide useful information in the fields of toxicology, pharmacology, oncology (tumor modeling), and neurology.
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Imaging in Translational Medicine: The BI Approach
Heiko Niessen, Ph.D., Translational Medicine Expert for Clinical Imaging, Translational Medicine, Boehringer Ingelheim Pharma GmbH & CO. KG
Similar to pre-clinical studies, pharmacodynamic endpoints in exploratory proof-of-concept studies are assessed using biomarkers, including imaging biomarkers. Therefore, translational imaging biomarkers are an important part of the clinical development program to foster and build hypothesis about the mechanism, to test the clinical concept, to differentiate programs with similar clinical outcome, to support go/no-go decisions, and to de-risk large investments.
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
Image Analysis: Problems and Solutions
Matt Silva, Ph.D., Director, Research Imaging Sciences, Amgen
fMRI for Drug Discovery: Potentials and Pitfalls
Fuqiang Zhao Ph.D., Senior Research Scientist, Imaging, Merck Research Labs
Imaging for Drug Toxicity Screening
Guillaume Normand, Investigator II, Novartis Pharmaceuticals Corporation
Cerenkov Luminescence Imaging: Strengths and Limitations
Robbie Robertson, Scientist I, Biomedical Imaging Group, Millennium: The Takeda Oncology Company
5:40 End of Day
 6-9 pm DINNER SHORT COURSE:
Molecular Imaging in Drug Discovery and Development: Back to Basics *
- Strength and limitations of various imaging modalities
- Multimodality imaging
- Generation of imaging agents for optical, MR, and nuclear imaging
- Image analysis
Thomas Bocan, Ph.D., Senior Director, Pre-Clinical Imaging, Pharmatherapeutics Precision Medicine, Worldwide Research & Development, Pfizer, Inc.
* Separate Registration Required.
|
Day 1 | Day 2
Download World Pharma Congress Final Brochure or Download Molecular Imaging Brochure